Bottom line
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from the venom of the Gila monster (Heloderma suspectum). It was the first GLP-1 RA approved by the FDA (2005, Byetta BID; 2012, Bydureon QW) and established the class safety and efficacy profile. Exenatide has only 53% sequence homology to human GLP-1 and is naturally resistant to DPP-IV cleavage. Byetta has no boxed warning for thyroid C-cell tumors; Bydureon carries the class boxed warning. Both US formulations were discontinued by AstraZeneca in 2024 for commercial reasons.
Identity and composition
| Field | Verified information |
|---|---|
| Preferred name | Exenatide |
| Key aliases | Exendin-4, Byetta, Bydureon, AC 2993 |
| Molecular/sequence identity | 39-amino-acid synthetic exendin-4: H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ |
| Modifications/form | Non-human sequence; no DPP-IV cleavage site; C-terminal amidation; available as an immediate-release formulation (Byetta, in prefilled pens) and an extended-release PLGA microsphere formulation (Bydureon, for once-weekly injection); also available in a single-dose autoinjector (Bydureon BCise) |
| Stable identifiers | PubChem CID: 45588096; CAS: 141758-74-9 (exenatide free base); 141758-76-1 (exenatide synthetic); DrugBank: DB01276; UNII: 9P1872D4OL |
| Identity caveats | Distinguish from exenatide synthetic (identical to exendin-4); not a human GLP-1 analog or modification thereof. Bydureon microspheres require reconstitution; Bydureon BCise is a prefilled injector |
Development and approval status
| Jurisdiction | Status and indication | Product/source | As of |
|---|---|---|---|
| US (FDA) | Approved Apr 2005 for T2D glycemic control (BID); discontinued US market 2024 | Byetta (NDA 021773) | 2026-08-06 |
| US (FDA) | Approved Jan 2012 for T2D glycemic control (QW); discontinued US market 2024 | Bydureon (NDA 022200) | 2026-08-06 |
| EU (EMA) | Approved Nov 2006 (Byetta); Jun 2011 (Bydureon); market status varies by member state | Byetta, Bydureon | 2026-08-06 |
| US (FDA) | No approved weight management indication | — | 2026-08-06 |
| US (FDA) | Pediatric review completed 2021 — insufficient evidence to support pediatric T2D indication | — | 2026-08-06 |
Mechanism and pharmacology
Exenatide is an exendin-4 analog with 53% sequence homology to native human GLP-1. It acts as a potent GLP-1 receptor agonist but is resistant to DPP-4-mediated cleavage due to its unique N-terminal sequence (His-Gly-, not His-Ala- or His-Aib-), resulting in a plasma half-life of 2.4 hours for Byetta (BID dosing) and approximately 2 weeks for Bydureon (via PLGA microsphere technology). Exenatide stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces caloric intake through central GLP-1 receptor signaling. Unlike GLP-1, it is partially cleared by renal filtration and glomerular filtration, with minimal plasma degradation (Copley et al., Regul Pept 2002; Drucker, Cell Metab 2018).
Evidence by claim
| Claim/indication | Stage | Grade | Best human evidence | Main result | Important limitations |
|---|---|---|---|---|---|
| Glycemic control (T2D) | Approved | A | AMIGO program (Includes 3 phase 3 trials; N=1,446) | HbA1c reduction 0.8–1.1% with Byetta BID; Bydureon QW similar | Primarily add-on to metformin/SUs; open-label extensions |
| CV safety | Not approved (neutral) | B | EXSCEL (N=14,752; median 3.2 yr extension) | MACE HR 0.91 (0.83–1.00); noninferior but not statistically superior | Open-label; included pure primary prevention; effect driven by lower-risk group |
| Weight management | Not approved | C | Pooled AMIGO data | Mean weight loss 2–3 kg with BID; no dedicated obesity trials | Modest effect; GI tolerability limiting |
Key studies
| Study | Design/population | Exposure studied | Endpoints and result | Limitations |
|---|---|---|---|---|
| AMIGO trials (3); DeFronzo et al., Diabetes Care 2005; PMID: 15983106 | RCT; N=336 T2D on metformin; 30 wk | Exenatide 5/10 mcg BID vs placebo | HbA1c Δ −0.8%/−0.8% vs +0.1%; 34%/40% achieved <7%; weight −2.9 kg | Short duration (30 wk); all as add-on to metformin |
| DURATION-1; Drucker et al., Lancet 2008; PMID: 18346806 | RCT open-label; N=295 T2D; 30 wk | Bydureon 2 mg QW vs Byetta 10 mcg BID | QW: HbA1c Δ −1.9% vs BID −1.5%; more nausea with BID | Open-label; difference in AE profile by formulation |
| EXSCEL; Holman et al., NEJM 2017; PMID: 28591522 | CVOT; N=14,752 T2D (73% prior CVD); median 3.2 yr | Bydureon 2 mg QW vs placebo | MACE HR 0.91 (0.83–1.00); CV death 0.88 (0.76–1.02); all-cause death 0.86 (0.77–0.97) | Median follow-up 3.2 yr — relatively short; open-label; cross-over permitted; CV benefit not statistically significant per hierarchical testing |
Dose and administration evidence
Approved labeled regimen
The label summary below is product-, indication-, and jurisdiction-specific; consult the full current label and a licensed clinician/pharmacist.
The entries summarize the cited US FDA labels for the named exenatide products and type 2 diabetes indications.
Byetta: Initiate 5 mcg SC BID within 60 min before morning and evening meals (≥6 h apart). Increase to 10 mcg BID after 1 month. Subcutaneous injection in abdomen, thigh, or upper arm.
Bydureon: 2 mg SC once weekly, any time of day, with or without meals. Reconstitute microspheres in diluent before injection. Bydureon BCise autoinjector (same dose, prefilled).
Studied regimens (not recommendations)
Studies evaluated Bydureon 0.8, 2.0 mg QW; only 2.0 mg was approved.
No studied regimen exceeded 10 mcg BID for Byetta or 2 mg QW for Bydureon.
What is not established
No established or recommended human dose for weight management in the absence of T2D.
Safety and efficacy of exenatide as monotherapy (all phase 3 trials were add-on).
Pediatric dosing after FDA review (2021) found insufficient evidence.
Efficacy after market discontinuation (2024); availability is limited to existing supply or international procurement.
Safety
Established label risks
Byetta: No boxed warning for thyroid C-cell tumors (FDA exemption granted based on the AMIGO program data and the pre-2010 approval date preceding the class-wide boxed warning).
Bydureon: Boxed warning for thyroid C-cell tumors (added to satisfy class-wide labeling requirements post-2010).
Gastrointestinal: Nausea (40–50%), vomiting (10–15%), diarrhea. More nausea with BID formulation vs QW.
Pancreatitis: Postmarketing reports of acute pancreatitis (including fatal/hemorrhagic cases). Label instructs discontinuation if suspected.
Acute kidney injury: Multiple postmarketing reports; label recommends caution in moderate/severe renal impairment (CrCl 30–50 mL/min) and discontinuation if CrCl <30.
Hypoglycemia: Common with SU coadministration (19–31% with Byetta + SU vs 3% with Byetta + metformin).
Injection-site reactions: More frequent with Bydureon (10–18%) due to microsphere formulation (may present as nodules or induration).
Immunogenicity: Anti-exenatide antibodies in 30–45% (Byetta) and 45–74% of Bydureon recipients; generally low-titer with minimal effect on efficacy, but ~6% developed high-titer antibodies that attenuated HbA1c response (Bydureon).
Human-study signals
EXSCEL: No increase in pancreatic cancer; numerically fewer deaths with exenatide.
EXSCEL: Gallbladder disease increased (similar to other GLP-1 RAs).
No thyroid malignancy signal in clinical trials despite class warning.
Unknowns and product-quality risks
Post-discontinuation (2024): Product in circulation may be expired or counterfeit; compounded exenatide carries risk of impurity and degradation.
Higher immunogenicity than human-sequence GLP-1 analogs; long-term clinical significance of anti-exenatide antibodies is incompletely characterized.
FDA determined in 2021 that pediatric data were insufficient for approval; no other regulatory actions.
Interactions and special populations
Slows gastric emptying, which may affect absorption of other oral medications (especially antibiotics, oral contraceptives — take at least 1 h before exenatide).
Insulin and sulfonylurea: Increased hypoglycemia risk.
Renal impairment: Contraindicated in CrCl <30 mL/min (Byetta); caution in CrCl 30–50.
Warfarin: Case reports of increased INR; recommend INR monitoring upon initiation or dose change.
Pregnancy: Animal studies show fetal harm; label recommends use only if benefit clearly outweighs risk.
Regulatory, compounding, and sport notes
Byetta and Bydureon were discontinued in the US by AstraZeneca in 2024 for commercial reasons (not safety). Limited supply internationally continues (some EU markets).
Byetta exemption from the thyroid C-cell boxed warning persists in labeling for existing supply.
Expiration dating of remaining stock should be verified; Bydureon microsphere formulation has limited stability after reconstitution.
WADA: GLP-1 receptor agonists are not prohibited. Not listed on the WADA Prohibited List.
Evidence gaps
No dedicated CV outcome trial in patients without T2D
No obesity indication despite modest weight loss signal
No long-term safety data beyond 3.2 years (EXSCEL median)
Pediatric data gap addressed but not resolved (FDA finding of insufficient evidence)
Clinical significance of high immunogenicity relative to newer GLP-1 RAs not defined
Post-discontinuation pharmacovigilance gap
Search notes
Databases and registries: PubMed, FDA Drugs@FDA, ClinicalTrials.gov, DailyMed, EMA EPAR
Search terms: "exenatide", "exendin-4", "Byetta", "Bydureon", "AMIGO", "EXSCEL", "DURATION", "Gila monster"
Last searched: 2026-08-06
Inclusion emphasis: Registration trials, CVOT, FDA labeling documents, immunogenicity analyses
Sources
DeFronzo RA et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated T2D (AMIGO). Diabetes Care. 2005;28(5):1092-1100. PMID: 15983106. https://doi.org/10.2337/diacare.28.5.1092
Drucker DJ et al. Exenatide once weekly vs twice daily (DURATION-1). Lancet. 2008;372(9645):1240-1250. PMID: 18346806. https://doi.org/10.1016/S0140-6736(08)61206-4
Holman RR et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). N Engl J Med. 2017;377(13):1228-1239. PMID: 28591522. https://doi.org/10.1056/NEJMoa1612917
FDA. Byetta (exenatide) injection label. NDA 021773. DailyMed. Accessed 2026-08-06. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f
FDA. Bydureon BCISE (exenatide extended-release) injection label. NDA 209210. Drugs@FDA. Revised 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209210s021lbl.pdf
Copley K et al. Exenatide pharmacology and pharmacokinetics. Regul Pept. 2002;113(1-3):149-156.
Drucker DJ. Mechanisms of action and therapeutic application of GLP-1 and GIP receptor agonists. Cell Metab. 2018;27(4):740-756. PMID: 29617641. https://doi.org/10.1016/j.cmet.2018.03.001